781664-81-1

Basic information

• Product Name: (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido
• Synonyms: (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido;Trityl valsartan methyl ester;(S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanam;L-Valine,N-(1-oxopentyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, methyl ester;(S)-Methyl 3-methyl-2-(N-((2-(1-trityl-1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)pentanamido)butanoate
• CAS NO: 781664-81-1
• Molecular Formula: C₄₄H₄₅N₅O₃
• Molecular Weight: 691.8598
• EINECS: 1312995-182-4
• Mol File: 781664-81-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido(781664-81-1)
• EPA Substance Registry System: (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido(781664-81-1)

Safety Data

• Hazardous Substances Data: 781664-81-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido is used as a pharmaceutical candidate for [application reason]. Its complex structure and chiral nature may offer unique interactions with biological targets, making it a promising molecule for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido serves as a subject for studying the effects of stereochemistry on molecular properties and reactivity. Its trityl-1H-tetrazol-5-yl, biphenyl, and pentanamido groups may provide insights into the design of new synthetic pathways and the exploration of novel chemical reactions.
Used in Material Science:
(S)-Methyl 3-methyl-2-(N-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido may be utilized in material science for the development of new materials with specific properties. Its unique molecular structure could contribute to the creation of materials with tailored characteristics, such as improved stability, selectivity, or reactivity.

Upstream product

• 638-29-9 n-valeryl chloride 
• 143945-72-6 N-trityl-5-(2-bromophenyl)tetrazole 
• 883223-09-4 N-pentanoyl-N-[4-(4′,4′,5′,5′-tetramethyl-1′,3′,2′-dioxaborolan-2'-yl)benzyl]-L-valinemethyl ester 
• 894793-34-1 methyl N-[4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)phenyl-4-yl-methyl]-L-valinate 
• 144873-97-2 2-(N-triphenylmethyl-tetrazol-5-yl)-phenylboronic acid 
• 154750-11-5 N-(triphenylmethyl)phenyltetrazole 
• 1000986-63-9 N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]valine methyl ester oxalate 

Downstream Products

• 137863-17-3 methyl N-((2’-(1H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate 
• 596-31-6 methoxytriphenylmethane 
• 137862-53-4 N-pentanoyl-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]-methyl]-(L)-valine 

Relevant articles and documents

A short and efficient synthesis of valsartan via a Negishi reaction

An efficient synthesis of the angiotensin-II inhibitor valsartan (Diovan) is presented. Directed ortho-metalation of 5-phenyl-1-trityl-1H- tetrazole (6) and its Negishi coupling with aryl bromide 5 are the key steps of the synthesis. This method overcomes

New and improved manufacturing process for valsartan

A new and improved industrially viable manufacturing process for valsartan, an antihypertension drug, is described.

Process For the Preparation of Angiotensin II Antagonist

The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2′-(1H-tetra-zol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2′-(1-triphenylmethyl-tetra-zol-5-yl)biphenyl-4-yl]methyl]-L-valine me

AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONIST

The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methy]-L-valine methy

PROCESS FOR PREPARING VALSARTAN

Provided is a process for preparing valsartan and precursors thereof.

A process for the synthesis of valsartan

This invention relates to an improved process for preparing a valsartan, or a pharmaceutically acceptable salt thereof, or pharmaceutical preparation containing either entity wherein a compound of formula (II) or a salt thereof, is reacted with valine or

INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST

It comprises new substituted 4-valinylmethylphenyl boronic acids and their derivatives and also its preparation process. It also comprises a preparation process of Valsartan from such intermediates. The process comprises the reaction of the new 4-valinylmethylphenyl boronic compounds with a (halophenyl)tetrazole compound which proceeds with high yields. The process is particularly advantageous in its practical industrial realization because it avoids the use of azide derivatives and also the use of expensive biphenyl intermediates.